Genovis
22,8 SEK -0,22%1.663 investorer følger denne virksomhed
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Omsætning
-
EBIT %
-
P/E
24,26
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
GENO
Daglig lav / høj pris
22,5 / 23,2
SEK
Markedsværdi
1,49 mia. SEK
Aktieomsætning
642,78 t SEK
Volumen
28 t
Finanskalender
Delårsrapport
08.11.2024
Årsrapport
14.02.2025
Større aktionærerKilde: Millistream Market Data AB
| Ejer | Kapital | Stemmer |
|---|---|---|
| Mikael Lönn | 14,5 % | 14,5 % |
| State Street Bank And Trust Co, W9 | 5,8 % | 5,8 % |
| Ålandsbanken ABP | 5,6 % | 5,6 % |
| Tin Ny Teknik | 5,1 % | 5,1 % |
| Swedbank Robour Fonder | 4,7 % | 4,7 % |
| J.P. Morgan SE, Luxembourg Branch, W8IMY/NQI | 3,9 % | 3,9 % |
| Andra AP-Fonden | 3,4 % | 3,4 % |
| Avanza Pension | 2,7 % | 2,7 % |
| BNP Paribas †SA Luxembourg, W8IMY | 2,7 % | 2,7 % |
| Handelsbanken Microcap Sverige | 2,1 % | 2,1 % |
ViserAlle indholdstyper
Genovis AB: Half-Yearly Report January - June 2024
Genovis AB: Genovis Announces Strategic Divestment of Antibody Business to Leinco Technologies Inc.
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools